Dr Deepa Pakianathan has been in biotech VC for more than twenty years, having seen multiple cycles of biotech boom-and-bust. She gives us her assessment of the IO landscape, her best advice for capital raising and her insight based on how her past experiences with CEOs have informed her approach as a new CEO.
Lead Editorial
The Current State of the IO Fundraising Landscape from a Long-Time Biotech Investor
Featured Editorial
Editorial by Category
Clinical Trial Operations
View All
Implementing Adaptive Clinical Trial Designs to Shorten Timelines at BlueSphere Bio
Biogen on Digital Innovations to Increase Trial Access and Enhance Patient Experiences
Where Technology Is Reducing or Increasing Burden on the Clinical Trial Site Level
Advancing Dementia Medicine Development Using Digital Health Tech Maturity and Patient-Centric Measures
Immuno-Oncology and Cell Therapy
View All
Drug Delivery
View All
Patients as Partners in Clinical Research and Patient Access
View All
Biotech CMO/R&D Leadership
View All
CRAACO: Clinical Research as a Care Option
View All
Biogen on Digital Innovations to Increase Trial Access and Enhance Patient Experiences
Moderna on Building Its Patient Insights Framework from Scratch
Stamford Hospital’s Compensation Model for Physicians Participating in Research
Making Cell and Gene Therapy Accessible for Medicaid Enrollees: White Paper
Women Leadership in Biotech
View All
The Conference Forum Sees Record Growth in Attendees Across 2024 Events, Bringing Together Leaders in Medicine Development
Women Leadership in Immuno-Oncology: 2022 Celebration Series
Women Leadership in Immuno-Oncology: 2021 Celebration Series
